Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Evaluation of PCLs Using Three EUS-FNA Needles

NCT01711294 · View on ClinicalTrials.gov ↗

Study Summary

To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts.

Conditions Studied

Interventions

  • DEVICE 19 G Flex Needle
  • DEVICE 22 G Needle
  • DEVICE 19 G Needle

Study Locations (8)

Massachusetts

  • Massachusetts General Hospital — Boston
  • Beth Israel Deaconess Medical Center — Boston

Other

  • Changhai Hospital — Shanghai
  • Asian Institute of Gastroenterology — Hyderabad

Arizona

  • Mayo Clinic — Scottsdale

Florida

  • Mayo Clinic — Jacksonville

Indiana

  • Indiana University Medical Center — Indianapolis

New York

  • New York Presbyterian Hospital/Columbia University Medical Center — New York

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2013-01-08
Est. Completion 2019-12-18
Phase NA

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01711294

The ClinicalTrials.gov registry entry for NCT01711294 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Pancreatic Cystic Lesions appearing as the primary indexed condition, and to 3 interventions — of which 19 G Flex Needle is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01711294 reports 8 study locations spanning 6 distinct geographic areas — top geographies include Massachusetts, Other, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01711294 about?

NCT01711294 is a clinical study titled "Evaluation of PCLs Using Three EUS-FNA Needles". To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-m...

What is the current status of trial NCT01711294?

This trial is currently completed. It is a NA study. The enrollment target is 250 participants. The study started on 2013-01-08. Estimated completion is 2019-12-18.

What conditions does trial NCT01711294 study?

This clinical trial studies the following conditions: Pancreatic Cystic Lesions. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01711294?

The interventions under investigation include: 19 G Flex Needle (DEVICE), 22 G Needle (DEVICE), 19 G Needle (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01711294?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01711294 being conducted?

This trial has 8 study locations across Arizona, Florida, Indiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial